BD & Henry Ford Health Tie-Up to Enhance Community Pharmacy Experience
BDX partners with Henry Ford Health to deploy BD Rowa Vmax robots, aiming to streamline 24/7 pharmacy access in Michigan.
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Becton Dickinson ( NYSE:BDX ) , Biogen ( NASDAQ:BIIB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?
Hologic set to end sales of Fluoroscan InSight FD in 2025 but sees strong momentum from DXA systems and broader business growth.
Here's Why Becton Dickinson ( BDX ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now
This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?
BD and Henry Ford Health Sign Pharmacy Automation Partnership to Revolutionize Medication Storage and Prescription Delivery - Becton Dickinson ( NYSE:BDX )
FRANKLIN LAKES, N.J., Sept. 22, 2025 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) BDX, a leading global medical technology company, today announced a pharmacy automation partnership with Henry Ford Health to develop the health system pharmacy of the future, with an initial focus on a ...
Why Becton Dickinson ( BDX ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Value Investors Buy Becton, Dickinson and Company ( BDX ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SOLV Strong Q2 Results Signal Momentum: Is the Stock Worth Buying Now?
Solventum beats on Q2 earnings, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
BDX vs. MMSI: Which Stock Should Value Investors Buy Now?
BDX vs. MMSI: Which Stock Is the Better Value Option?
Hologic's 2025 Outlook Improves on Strong Q3, Easing Tariff Headwinds
HOLX lifts its 2025 revenue and EPS outlook on Q3 strength, tariff relief, and growth across Breast Health and GYN Surgical.
Are Options Traders Betting on a Big Move in Becton Dickinson Stock?
Investors need to pay close attention to Becton Dickinson stock based on the movements in the options market lately.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Becton Dickinson ( BDX ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy - Here's Where He's Investing Instead - Tesla ( NASDAQ:TSLA )
T. Rowe Price fund manager David Giroux warns Tesla remains severely overvalued. Giroux avoids Tesla, Palantir, Costco, Walmart; prefers healthcare, utilities, innovation picks. The market is reacting to Powell's speech. Learn how to time your next move. Details here →
[Latest] Global Chemical Reagents Market Size/Share Worth USD 26.5 Billion by 2034 at a 7.5 CAGR: Custom Market Insights ( Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis )
Austin, TX, USA, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled "Chemical Reagents Market Size, Trends and Insights By Product Type ( Solvents, Acids & Bases, Oxidizing & Reducing Agents, Buffers & Standards, Catalysts ) , By Application ( ...
Biobanking Market is expected to generate a revenue of USD 2.11 Billion by 2031, Globally, at 9.89% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- The Global Biobanking Market Size is projected to grow at a CAGR of 9.89% from 2024 to 2031, according to a new report published by Verified Market Research®.
Looking Into Becton Dickinson's Recent Short Interest - Becton Dickinson ( NYSE:BDX )
Becton Dickinson's BDX short percent of float has risen 16.67% since its last report. The company recently reported that it has 5.48 million shares sold short, which is 1.89% of all regular shares that are available for trading.
Here's Why Becton Dickinson ( BDX ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Becton Dickinson ( BDX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can Sustained Product Demand Drive CAH Stock Before Q4 Earnings?
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal fourth-quarter revenues despite an uncertain macroeconomic environment.
Company News for Aug 8, 2025
Companies in The Business Are: ...
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) EMBC, a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025.
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) ( Nasdaq: EMBC ) , a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025.
Becton Dickinson Q3 Beats Estimates On Medical Device Boom - Becton Dickinson ( NYSE:BDX )
Becton Dickinson Q3 EPS of $3.68 beats estimate of $3.41; revenue rose 10.4% to $5.51 billion. BD raises FY25 EPS guidance to $14.30-$14.45 vs consensus of $14.18. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Applovin, Sunrun, Duolingo, Tutor Perini, Installed Building Products And Other Big Stocks Moving Higher On Thursday - AppLovin ( NASDAQ:APP ) , Advanced Micro Devices ( NASDAQ:AMD )
U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Thursday. Shares of Applovin Corp APP rose sharply during Thursday's session following upbeat earnings. AppLovin reported second-quarter revenue of $1.26 billion, missing analyst estimates of $1.31 billion, according ...
BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up
BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
Becton Dickinson ( BDX ) Surpasses Q3 Earnings and Revenue Estimates
Becton Dickinson (BDX) delivered earnings and revenue surprises of +7.60% and +0.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical ( STAA ) Reports Q2 Loss, Beats Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of +87.50% and +6.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?
HOLX rises post earnings beat, fueled by Diagnostics strength and Surgical growth. However, macro headwinds persist.
Can Sustained Product Demand Drive BDX Stock Before Q3 Earnings?
BD's third-quarter fiscal 2025 results are likely to benefit from product launches across Medical and Interventional segments, which drive strong revenue potential.
Curious about Becton Dickinson ( BDX ) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
OraSure Appoints Anne Messing as Chief Commercial Officer
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) ( NASDAQ: OSUR ) , a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
OraSure Appoints Anne Messing as Chief Commercial Officer - OraSure Technologies ( NASDAQ:OSUR )
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) OSUR, a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
Earnings Preview: Becton Dickinson ( BDX ) Q3 Earnings Expected to Decline
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
There are no guarantees on Wall Street, especially when it comes to dividends. The board of directors of each company decides on the dividend in private. But income investors can glean some information from past dividend decisions, which is the only information available.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US - AstraZeneca ( NASDAQ:AZN )
AstraZeneca plans $50 billion in U.S. investment by 2030, including a drug facility in Virginia for its metabolic and weight loss portfolio. Company aims to generate 50% of $80 billion revenue from the U.S. by 2030 with new manufacturing and R&D expansions.
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing - Biogen ( NASDAQ:BIIB )
Biogen to invest $2 billion more in its RTP manufacturing, adding to $10B already spent in North Carolina. Expansion includes advanced automation, AI integration and multi-platform fill finish capabilities.
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research®
Lewes, Delaware, July 21, 2025 ( GLOBE NEWSWIRE ) -- The Global Sleep Apnea Devices Market Size is projected to grow at a CAGR of 10.42% from 2024 to 2031, according to a new report published by Verified Market Research®.
The Smartest Dividend Stock to Buy With $1,000 Right Now
If you are a dividend investor looking to maximize the income your portfolio generates, you will want to do a deep dive on Universal Health Realty Income Trust ( NYSE: UHT ) . It has a historically high 7.4% dividend yield and a great track record of dividend growth to back it up.
How Do Investors Really Feel About Becton Dickinson? - Becton Dickinson ( NYSE:BDX )
Becton Dickinson's BDX short percent of float has risen 21.62% since its last report. The company recently reported that it has 3.90 million shares sold short, which is 1.35% of all regular shares that are available for trading.
BD Partners With Waters to Build High-Volume Diagnostics Leader
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Monogram Technologies Inc. ( Nasdaq - MGRM ) , Veritex Holdings, Inc. ( Nasdaq - VBTX ) , ESSA Pharma Inc. ( Nasdaq - EPIX ) , Waters Corporation ( NYSE - WAT ) - Huntington Bancshares ( NASDAQ:HBAN )
BALA CYNWYD, Pa., July 14, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Why is Waters Stock Down On Monday? - Becton Dickinson ( NYSE:BDX ) , Waters ( NYSE:WAT )
BD's diagnostics business is projected to generate $3.4 billion in revenue and $925 million in adjusted EBITDA in 2025. Combined company expects $9 billion revenue, $3.3 billion adjusted EBITDA, and 32% margin by 2030. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
The Best High Yield Medical Device Stock to Invest $1,000 in Right Now
One of the good things about the healthcare sector is that most medical care isn't optional. This is the foundation behind the sector, but on that foundation sits the growth opportunity that comes with medical advances.Right now one of the best healthcare stocks to look at is medical device giant ...
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
Becton Dickinson Stock: Why It's Best to Avoid For Now - Becton Dickinson ( NYSE:BDX )
Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until early June 2027.
Infusion Pump Market is expected to generate a revenue of USD 24.09 Billion by 2031, Globally, at 6% CAGR: Verified Market Research®
Lewes, Delaware, June 23, 2025 ( GLOBE NEWSWIRE ) -- The Global Infusion Pump Market Size is projected to grow at a CAGR of 6% from 2024 to 2031, according to a new report published by Verified Market Research®.
New Jersey Rep. Thomas Kean Bought Over $4K Worth of Amazon.com Stock: Here's What You Should Know - Aon ( NYSE:AON ) , Amazon.com ( NASDAQ:AMZN )
An official report on June 17, 2025 reveals Representative Thomas Kean's recent purchase of Amazon.com AMZN stock, valued between $4,004 and $60,000. The transaction took place on May 8, 2025, as per the June filing. At this time, Amazon.com shares are trading up 1.37% at $217.76.
